Gilgamesh Pharma, a clinical-stage neuroscience company focused on transforming psychiatric treatment, today announced positive topline results from its Phase 2a study of blixeprodil (GM-1020).
The FDA approved combination dextromethorphan and bupropion extended-release tablets (Auvelity) for adults with major depressive disorder (MDD), Axsome Therapeutics announced on Friday.
AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared to placebo starting at one week1-4 AUVELITY ...
Glutamate levels increase in early psychosis but normalize over time, challenging established perspectives on schizophrenia progression. The study involved treatment-naive patients, isolating natural ...
Drugs that act on NMDA (N-methyl-D-aspartate) receptors, which are essential for learning, memory and moment-by-moment consciousness, are key for treating neuropsychiatric disorders. These drugs were ...
Despite growing off-label use, ketamine and related NMDA blockers show no reliable evidence of easing chronic pain, highlighting the urgent need for safer and more effective treatments. Review: ...
The images showed that nearly all the antibodies bind to a single domain of the receptor, providing a viable target for novel therapeutics.
The links between neurons are crucial to the brain, and brain cells can reorganize the way they are linked together in a phenomenon known as neuroplasticity. This process is ongoing during a lifetime, ...
ATLANTA--(BUSINESS WIRE)--NeurOp, Inc., a clinical-stage biotechnology company focused on neurological and psychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback